A British Journal of Pharmacology review published January 2026 examining GLP-1 receptor agonists and muscle strength changes in older adults concluded that "future randomized, double-blinded trials with adequate sample sizes and longer follow-ups are warranted, particularly in older populations who are at an increased risk of sarcopenia." Where the Risk Is Highest The risk is highest for older adults who: Are already at or near the threshold for sarcopenia (low baseline muscle mass and strength) before starting a GLP-1 drug Lose weight rapidly, at more than 1.5 kg per week, which amplifies lean mass loss relative to fat Do not engage in resistance exercise during treatment, which is the primary protective intervention against muscle loss on GLP-1 drugs Have low baseline protein intake or difficulty increasing protein consumption due to reduced appetite on the drug Have multiple chronic conditions requiring several concurrent medications, increasing the risk of drug interactions and compounding dehydration Are over 75, for whom functional decline from muscle loss has more immediate consequences for independence Geographically, older adult populations in Sun Belt metro areas (Phoenix, Miami, Tampa, Las Vegas, Jacksonville, and others) are among the highest-density Medicare populations in the country, and the regions where GLP-1 prescribing is growing fastest in newly eligible Medicare enrollees
Creams and serums are applied by pump, drop, or a consistent fingertip amount
Redox-sensitive micelles co-deliver TMZ/ -lapachone to GBM, cleaving disulfides in GSH-rich tumors, whereas pH triggers endosomal escape (142)
In the context of gut health, peptide bioregulators can influence epithelial integrity, support tissue regeneration, modulate immune responses, and indirectly shape the gut microbiome by creating a more balanced intestinal environment
